Joining us again on The Daily Dive is Dr. Thomas Sawyer, COO of Cognetivity Neurosciences (CSE: CGN). Today, Tom sits down with Cassandra to talk about their recent partnership with SEHA, the UAE’s largest healthcare network, developments in the deployment of CognICA, and more updates on the future of brain health screening.
Cognetivity Neurosciences is a tech firm that has developed a cognitive testing platform for use in medical, commercial, and consumer environments. Through the use of AI and machine learning, the tech is able to detect the early onset of Alzheimer’s and dementia through testing the performance of large areas of the brain. The tech has acquired regulatory approval for use in both the UK and Europe, with further approvals in North America anticipated to occur.
FULL DISCLOSURE: Cognetivity Neurosciences Ltd is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Cognetivity Neurosciences Ltd on The Deep Dive, with The Deep Dive having full editorial control. We may buy or sell securities in the company at any time. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
